The FDA has issued two draft guidance documents outlining recommendations for the use of artificial intelligence in the development and marketing of drugs, biologics, and medical devices, emphasizing transparency, bias mitigation, and ongoing performance monitoring to ensure safety and effectiveness.
View full story…
FDA Releases Draft Guidance on AI Integration in Drug Development and Medical Devices
